Paclitaxel, bropirimine and linomide: Effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms

Michael Shaw, Saki Ratanawong, Pauline Chou, Vera Ray, Yelena Mirochnik, Leonid Slobodskoy, Marvin Rubenstein, Patrick Guinan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression also significantly depressed tumor necrosis factor-α (TNF-α) expression. In the bropirimine treated group there was also a correlation between angiogenesis and cyclin D expression. Finally, linomide significantly decreased angiogenesis. Since the mechanism of action of these drugs differ, combining them at lower doses might maintain therapeutic efficacy while reducing toxicity.

Original languageEnglish (US)
Pages (from-to)111-114
Number of pages4
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume20
Issue number2
DOIs
StatePublished - Mar 1 1998

Keywords

  • Bropirimine
  • Chemotherapy
  • Linomide
  • Paclitaxel
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'Paclitaxel, bropirimine and linomide: Effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms'. Together they form a unique fingerprint.

Cite this